POSTER PRESENTATION ABSTRACTS
Please note: All posters will be displayed in
Salons 10-12.
THURSDAY, 5:30-6:15 PM
Smith JA, Zu Z, Kunther A, Liu L, Meng Z, Wolf JK, Gaikwad
A, Cohen L.
In vitro evaluation of HuaChanSu alone and in combination
with antineoplastic agents in human ovarian and endometrial cancer cell
lines.
UT MD Anderson Cancer Center jasmith@mdanderson.org
PURPOSE: Compare and contrast the growth inhibitory
activity of selected anticancer agents when administered alone versus
in combination with HuaChanSu.
METHODS: Cell growth inhibition was determined
by the standard MTT assay and an IC50 was calculated for docetaxel,
paclitaxel, topotecan, gemcitabine and carboplatin in four human ovarian
cancer cell lines (SKOV3, ES-2, TOV-21G, and OV-90) and four human endometrial
cancer cell lines (Hec-1A, Hec-1B, MES-SA, RL95). The ICX was defined
as the drug concentration required for X% reduction in optical density.
Cytotoxic assays are being performed with the following combinations
of each taxane and platinum compound. In each combination, cell lines
were treated with an appropriate IC10, IC50 or IC90 of the for 72 hours.
Optical density for each samples was measured at absorbance at 570 nm.
RESULTS: The 50% growth inhibitory concentration
(IC50) of HuaChanSu single agent in human ovarian cancer cell line panel
and endometrial cancer cell line panel ranged from 0.8 Ð 2.4 units/mL
and 1.5 Ð 1.7 unit/mL, respectively. When the ovarian and endometrial
cancer cell lines were treated with HuaChanSu at varying concentrations
(IC25, IC50, IC90) in combination with respective concentrations paclitaxel,
docetaxel, carboplatin, topotecan or gemcitabine a 10% to 50% increase
in growth inhibitory activity was observed compared to either agent
alone.
CONCLUSIONS: The data from this initial in vitro
study evaluating the combination of HuaChanSu with antineoplastic agents
commonly used in the treatment of gynecologic cancers suggests that
HuaChanSu, a well tolerated natural toad skin extract, adds to the cytotoxicity
activity of these agents. In vivo animal studies are planned to confirm
these in vitro data and continue efforts to integrate active agents
from traditional Chinese medicine with modern Western medical treatment
regimens.
Back